Compare Cardinal Health Inc (CAH) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Sony Group Corp — how do they compare? Cardinal Health Inc trades at $237.02 (market cap $55.88B), while Sony Group Corp trades at $23.44 (market cap $138.43B). The key difference: Sony Group Corp is far larger — about 2.5× Cardinal Health Inc's market cap, and Cardinal Health Inc pays the higher dividend (0.86%). Which is the better fit depends on your goals.
| CAH | SONY | |
|---|---|---|
Market Cap | $55.88B | $138.43B |
Sector | Health | Technology |
52-Week High | $240.26 | $30.26 |
52-Week Low | $146.04 | $19.32 |
Enterprise Value | $59.91B | $136.35B |
Dividend Yield | 0.86% | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.
Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.
Sony (SONY) trades at $23.82, up 1.53% over the past day, with a bullish technical signal from moving averages and oscillators. Recent earnings show mixed quarterly results, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. The company reported strong operating cash flow of $2.32 trillion in 2025, though net income margin turned negative at -1.75% for 2026. Positive sentiment is driven by blockbuster Spider-Man performance and a joint venture with TSMC for image sensors.
The outlook is cautiously optimistic, supported by analyst consensus with 68.75% buy ratings and a 29.75% upside potential. Key opportunities include growth in gaming and sensors, while risks involve profitability pressures and competitive threats. Investors should weigh strong cash flow against margin volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
